## -online.com genomics





## Human HLA-L CRISPR gRNA + Cas9 in Lenti Particles

Overview	
Quantity:	300 μL
Gene:	HLA-L
Species:	Human
Insert:	gRNA + Cas9
Vector:	Lentiviral Vector
Application:	Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)
Product Details	
Purpose:	Individual gRNA against HLA-L in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and
	Cas9 in a single vector)
Vector Backbone:	pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Promoter:	U6 Promoter, SFFV Promoter
Selectable Marker:	Puromycin
Bacterial Resistance:	Ampicillin
Expression Type:	Stable, Transient
Sequence:	Sequence available upon placing order
Specificity:	GRNAs are designed for use with Cas9 Nuclease only.
	Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority
	of cells, except ES cells or iPS cells.
Sequencing Primer:	U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'
Components:	Lentiviral particles with an individual gRNA (300 μL) for a specific sequence of HLA-L

## **Target Details** HLA-L Gene: Alternative Name: HLA-L NCBI Accession: NG\_002771 **Application Details** Application Notes: Recommended for quality control: Restriction Enzyme Digest and Sequencing Restrictions: For Research Use only Handling Viral Particles Format: -80 °C Storage: Expiry Date: 12 months

Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (

**Publications** 

Product cited in:

1991)